In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system
EuroIntervention 2016;12:740-747 published online ahead of print October 2015. DOI: 10.4244/EIJY15M10_01
Juan F. Granada1*, MD; Armando Tellez1,2, MD; William R. Baumbach3, PhD; Brendan Bingham3, MA; Yen-Fang Keng3, PhD; Jeffrey Wessler4, MD; Gerard Conditt1, RCIS; Jennifer McGregor1, BS; Gregg Stone4, MD; Greg L. Kaluza1, MD, PhD; Martin B. Leon4, MD
1. CRF-Skirball Center for Innovation, Orangeburg, New York, NY, USA; 2. Alizee Pathology, Thurmont, MD, USA; 3. Caliber Therapeutics, New Hope, PA, USA; 4. Columbia University Medical College, New York, NY, USA
Aims: Among antirestenotic compounds, sirolimus displays a superior safety profile compared to paclitaxel, but its pharmacokinetic properties make it a challenging therapeutic candidate f